Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. by Mari Aparici, Carina et al.
Lawrence Berkeley National Laboratory
Recent Work
Title
Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience.
Permalink
https://escholarship.org/uc/item/0vz14243
Authors
Mari Aparici, Carina
Behr, Spencer C
Seo, Youngho
et al.
Publication Date
2017
DOI
10.1177/1536012117723256
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Brief Report
Imaging Hepatocellular Carcinoma With
68Ga-Citrate PET: First Clinical Experience
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R. Kate Kelley, MD2, Carlos Corvera, MD3, Kenneth T. Gao1,
Rahul Aggarwal, MD2, and Michael J. Evans, PhD1,2,4
Abstract
While cross-sectional imaging with computed tomography (CT) and magnetic resonance imaging is the primary method for
diagnosing hepatocellular carcinoma (HCC), they provide little biological insight into this molecularly heterogeneous disease.
Nuclear imaging tools that can detect molecular subsets of tumors could greatly improve diagnosis and management of HCC. To
this end, we conducted a patient study to determine whether HCC can be resolved using 68Ga-citrate positron emission
tomography (PET). One patient with recurrent HCC was injected with 300 MBq of 68Ga-citrate and imaged with PET/CT 249
minutes post injection. Four (28%) of 14 hepatic lesions were avid for 68Ga-citrate. One extrahepatic lesion was not PET avid. The
average maximum standardized uptake value (SUVmax) for the lesions was 7.2 (range: 6.2-8.4), while the SUVmax of the normal
liver parenchyma was 4.7 and blood pool was 5.7. The avid lesions were not significantly larger than the quiescent lesions, and a
prior contrast CT showed uniform enhancement among the lesions, suggesting that tumor signals are due to specific binding of
the radiotracer to the transferrin receptor, rather than enhanced vascularity in the tumor microenvironment. Further studies are
required in a larger patient cohort to verify the molecular basis of radiotracer uptake and the clinical utility of this tool.
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Introduction
Hepatocellular carcinoma (HCC) is the most common type of
liver cancer and the third most common cause of cancer-related
deaths.1 Asymptomatic progression and thus difficult early
detection, as well as underdeveloped therapeutic strategies,
contribute to the very high fatality of HCC. Moreover, recent
large-scale tissue studies have suggested that HCC can be
classified as molecular subtypes with discrete tumorigenic
profiles.2 On this basis, there is an urgent need to improve
diagnostic strategies to empower the best treatment planning
for this heterogeneous and very fatal disease.
While cross-sectional imaging with computed tomography
(CT) and magnetic resonance imaging is the primary method
for diagnosing HCC, they provide little insight into tumor biol-
ogy. We hypothesized that nuclear imaging tools capable of
detecting tumors with actionable oncogenic drivers could
greatly improve diagnosis and management of this highly fatal
cancer. Consistent with this hypothesis, radiotracers such as
18F-fluorodeoxyglucose (18F-FDG) and 18F-fluorocholine
have been found to be beneficial for the detection of HCC and
the determination of tumor differentiation in situ. However, the
molecular basis of HCC avidity for these radiotracers is not
known, and they do not yet provide additional biological infor-
mation about the tumor subtype that might guide clinical deci-
sion-making.3,4
As part of a larger research program to develop probes for
nuclear imaging to study the activity of central oncogenes,5 we
and others have shown in preclinical models and clinical biop-
sies that the transferrin receptor (TFRC) is upregulated in
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tumors with important oncogenic drivers like the transcription
factor MYC and the cytosolic Ser/Thr kinase mammalian target
of rapamycin (mTOR).6-8 Hepatocellular carcinoma frequently
harbors MYC and mTOR hyperactivity. These data led us to
conduct the first human study to test whether any HCC tumors
detectable with positron emission tomography (PET) targeting
TFRC. 68Ga(III) is an Fe (III) biomimetic and potently and
selectively binds to apotransferrin in blood,9 forming 68Ga-
transferrin. To establish whether HCC tumors harbor high avid-
ity for radiolabeled transferrin, we opened a protocol at Uni-
versity of California, San Francisco (UCSF) testing whether
HCC could be detected with 68Ga-citrate PET.
We recently reported the first guidelines for 68Ga-citrate
PET detection of castration-resistant prostate cancer metas-
tases.10 We found that >130 MBq (or 3.5 mCi) and acquisitions
>180 minutes post injection were required for suitable image
quality and tumor resolution. During this study, a visceral pros-
tate cancer metastasis in the liver was also detected, showing
that tumors can be resolved against the background of normal
liver, which also expresses high levels of the TFRC.
Methods
Positron Emission Tomography/CT Technique
Informed consent was obtained prior to enrolling the patient for
this study. The study was approved by the institutional review
board at UCSF. 68Ga-citrate 300 MBq (8.11 mCi) was injected
intravenously. After 249 minutes of injection, a PET/CT was
performed on a Discovery VCT PET/CT scanner (GE Health-
care, Waukesha, Wisconsin) with an integrated PET and
64-multidetector CT scanner. First, a single-bed PET acquisition
over the liver was obtained for 10 minutes, followed by whole-
body PET from vertex to thighs over 8 bed stations. Each PET
was acquired for 4 minutes per bed station. A low-dose CT was
obtained for attenuation correction only. Positron emission
tomography images were reconstructed in a transverse matrix
of 128 128, using a postreconstruction filter (8 mm Full Width
at Half Maximum Gaussian), 14 subsets and 6 iterations of an
ordered-subsets expectation maximization algorithm.
Positron emission tomography images were reviewed on an
Advantage Workstation (GE Healthcare) by a dually trained
abdominal radiologist and nuclear medicine physician with
over 10 years interpreting PET (S.C.B.) and prior experience
interpreting 68Ga-citrate PET data. Maximum and average
standardized uptake values (SUVmax and SUVave) were deter-
mined in the uninvolved liver and left ventricle by drawing a
circular region of interest (diameter ¼ 1 cm). Hepatic lesions
were considered positive if they were visually detectable above
normal liver uptake of the radiotracer. For positive HCC
lesions, SUVmax was determined by drawing a 3-dimensional
volume of interest encompassing the entire lesion.
Since the CT portion of the PET/CT was performed as low-
dose CT, a multiphase diagnostic CT of the abdomen and
pelvis performed 1 month prior to 68Ga-citrate PET/CT was
used to assess the number and size of the lesions.
Results
A 27-year-old man with a history of Crohn disease and treated
with azathioprine was consented for this study. Three years
prior to this study, a left hepatic lobe lesion was found during
a magnetic resonance enterography. A multiphase CT showed
2 masses in hepatic segment 4 with imaging features consistent
with HCC, whereupon the patient was treated with partial left
hepatectomy. The patient was found to have recurrent multi-
focal disease in the right hepatic lobe on subsequent examina-
tions. The most recent multiphase CT performed 1 month prior
to the 68Ga-citrate PET/CT showed persistent, multifocal dis-
ease in the residual left hepatic as well as an abdominal wall
implant. At the time of PET/CT, the patient’s serum a-fetopro-
tein concentration was 5755 mg/L.
Following our guidelines developed for prostate cancer, we
injected the patient with 300 MBq (or 8.11 mCi) of 68Ga-citrate
intravenously. After 249 minutes, the patient was imaged with
PET/CT over multiple bed stations to determine the biodistri-
bution of 68Ga-citrate.
A summary of the lesion size and SUVmax is outlined in
Table 1. The average size of the lesions was 4.2 + 1.8 cm
(range: 1.7-6.9 cm). Four (28%) of 14 lesions were PET avid
(Figure 1). The average size of the PET avid lesions was 4.7+
1.7 cm (range 2.7-6.5 cm). The average size of the quiescent
lesions was 3.9+ 1.9 (range: 1.7-6.9). The average SUVmax of
the PET avid lesions was 7.5 + 1.2 (range: 6.2.-8.9). The
average SUVmax of the quiescent lesions was 3.2+ 0.8 (range:
1.7-4.2; see Figure 2A-C). An anterior abdominal wall implant
was the only site of extrahepatic disease. It measured 2.8 cm
and was not PET avid (SUVmax ¼ 2.7).
Each of the PET avid lesions had SUVmax values exceeding
those of blood pool, liver, and normal reference tissues. Blood
pool SUVmax and SUVave were 5.7 and 3.6, respectively. The
SUVmax and SUVave of the normal, uninvolved hepatic par-
enchyma were 4.3 and 2.7, respectively. The SUVmax and
SUVave of the right paraspinal muscle were 0.6 and 0.4, while
Table 1. Summary Table of liver lesions.
Segment Location Size (cm) SUVmax PET Avid
8 6.9 3.3 No
7 6.1 3.6 No
7 2.8 1.8 No
7 5.7 3.2 No
7 2.8 4.2 No
7 2.5 4.1 No
7 2.7 7.9 Yes
7 5.7 6.2 Yes
6 1.8 3.4 No
6 1.7 3.6 No
6 3.7 8.9 Yes
5 4.3 2.9 No
5 5.2 1.7 No
1 6.5 6.9 Yes
Abbreviations: PET, positron emission tomography; SUVmax, maximum
standardized uptake value.
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the SUVmax and SUVave of the right sacrum were 1.9 and 1.6,
respectively. Focal uptake (SUVmax¼ 7.2) was seen in the T11
vertebral body compression deformity perhaps due to inflam-
mation (Figure 2D).
Discussion
In this study, we showed that HCC can be detected by adminis-
tering a PET/CT after injection of 68Ga-citrate. Approximately
30% of lesions were avid for the radiotracer, which is not unex-
pected given the molecularly heterogeneous landscape of this
disease. Tumor uptake of the radiotracer exceeded that of blood
pool at 4 hours, demonstrating the rapid dissemination of trans-
ferrin into peripheral tissues. Moreover, despite the high expres-
sion of TFRC in normal hepatocytes, HCC lesions within the
liver could be clearly resolved against the normal liver parench-
yma. Lastly, 1 nonmalignant focus of radiotracer uptake was
observed and readily distinguishable from malignancy by CT.
Although 68Ga-transferrin can accumulate in abscesses with
abnormal vascularity,11 several lines of evidence show that
uptake in the tumor microenvironment is due to specific recep-
tor binding rather than the enhanced permeability and retention
effect (EPR). First, the magnitude of tumor uptake exceeds
blood pool, which itself is somewhat high, and the tumor
uptake is above the range of what might be considered EPR.12
In preclinical models, 89Zr-albumin has been used to quantify
signal due to EPR in subcutaneous xenografts, and the highest
uptake observed was *5% ID/g.12 Second, the contrast
enhancement observed on this patient’s staging CT was uni-
form across the 14 hepatic lesions, yet only 4 lesions were PET
avid. If 68Ga-transferrin localization to the tumor were due to
EPR, one could reasonably expect roughly equal accumulation
of the radiotracer in all 14 hepatic lesions and values roughly
equivalent to blood pool activity.
The relatively high blood pool activity observed at 4 hours
post injection underscores that 68Ga(III) in serum exists bound
within a large biomolecule and does not circulate in the free salt
form. This is consistent with the long-standing pharmacologi-
cal model that 68Ga(III) exclusively binds apotransferrin in
serum, both owing to the presence of a high affinity metal
binding site and the overall high abundance of apotransferrin
in serum.13 Persistent blood pool activity also highlights the
need for further refinement of the imaging protocol. We are
currently increasing the injected dose beyond 300 MBq and
imaging at later time points post injection to determine any
improvement in signal to noise.
Whether there is a component of 68Ga-transferrin uptake in
the tumor microenvironment due to infiltrating peripheral
blood mononuclear cells is currently not understood. Future
studies are required to acquire the tissue needed to address,
in particular, to determine the specificity of 68Ga-transferrin
for HCC versus sites of inflammation. That said, should the
radiotracer biodistribution be attributable to leukocyte accumu-
lation in the tumor microenvironment rather than tumor auton-
omous TFRC expression, the observation that the leukocytes
only measurably accumulated in 4 of 14 hepatic lesions is
thought-provoking and could provide the foundation for
hypothesis-driven research on the mechanism of leukocyte
tropism to tumors.
Figure 1. A maximum intensity projection showing multiple foci avid
for 68Ga-transferrin. Tumor lesions are indicated with black arrows.
The linear uptake corresponds to uptake from a vertebral body
compression fracture (black arrow head).
Figure 2. Representative images of 68Ga-transferrin uptake in tumor and normal structures. A, An axial PET/CT demonstrating variable uptake
in 3 different hepatic masses. The most avid lesion (black arrow) corresponds to the 2.7 cm  1.3 cm (SUVmax ¼ 7.9) on the prior contrast-
enhanced CT. A second lesion just medial to this (white arrow) is 5.7 cm  5.7 cm, though had less radiotracer uptake (SUVmax ¼ 6.2). A third
lesion in the caudate lobe (*) measured 6.5 cm 6.3 cm with uptake similar to uninvolved liver (SUVmax¼ 3.5). Focal uptake in the spine (white
arrow head) corresponds to the vertebral body compression deformity seen on sagittal CT. B, The corresponding CT collected during the PET/
CT acquisition. C, The contrast-enhanced CT collected 1 month prior to the PET/CT. D, A sagittal view of the CT showing the vertebral body
compression. CT indicates computed tomography; PET, positron emission tomography; SUVmax, maximum standardized uptake value.
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Because conventional radiographic response assessment is
unreliable in HCC and some tumors may not be amenable to
biopsy due to location or risk of tumor seeding, improved
noninvasive imaging modalities are greatly needed for diagno-
sis as well as response assessment in HCC. Nuclear imaging
tools, including 18F-FDG, 18F- or 11C-choline, 11C-acetate, and
radiolabeled analogues of glutamine, have been studied in
humans.14-16 The current body of data suggests that 18F-
choline and glutamine derivatives like F18-(4S)-4-(3-
[18F]fluoropropyl)-L-glutamate may prove most useful for
measuring tumor burden regardless of tumor subtype or differ-
entiation. Developing a radiotracer that uniquely targets a mole-
cular subtype of HCC could synergize well with these
technologies. Future studies in a larger patient cohort are
required to verify with the molecular analysis of tissue biopsies
the biological basis of 68Ga-transferrin uptake. Following the
example of previous radiomic studies in the field,8 we are opti-
mistic that the biological drivers of transferrin uptake can be
defined by comparing the differences in gene expression patterns
among PET avid and quiescent HCC lesions. Validating which
genes are responsible for the PET avid versus quiescent pheno-
type can be further tested in preclinical cancer models.
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